



BERYL DRUGS LIMITED

Regd. Off.: Ground Floor, 133, Kanchan Bagh, Indore - 452001 (M.P.)

Tel. : (0731) 2517677 | E-mail : beryldrugs25@yahoo.com | CIN : L02423MP1993PLC007840

Date: 11-05-2026

To,
DCS-Listing
The Bombay Stock Exchange Limited,
Phiroze JeeJeebhoy Towers,
Dalal Street,
Mumbai- 400001

Scrip Code: 524606

ISIN: INE415H01017


Sub: Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 – Approval of Shareholders for Regularisation of Appointment of Mr. Shailendra Pathak(DIN: 11169772) as Whole-Time Director

Dear Sir/Madam,

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the shareholders of the Company at the Extra-Ordinary General Meeting ("EGM") held on 11th May, 2026 at 11:00 A.M. Concluded at 11:30 A.M. at Kanchan Palace, Community Hall, Nipania Ring Road, Indore- 452001 have approved the regularisation of appointment of Mr. Shailendra Pathak as Whole-Time Director of the Company.

The details as required under SEBI Circular bearing reference no. CIR/CFD/CMD/4/2015 dated September 09, 2015 are enclosed hereunder:

Particulars	Details
Name of Director	Mr. Shailendra Pathak (DIN: 11169772)
Designation	Whole-Time Director
Reason for Change	Regularisation/Approval of appointment by shareholders
Date of Appointment & Term	For a period of 5 years from the conclusion of EGM
Brief Profile	Mr. Shailendra Pathak is having more than 35 years of experience in pharmaceutical industry
Disclosure of Relationships between Directors	Mr. Shailendra Pathak is not related to any Director of the Company.
Information as required pursuant to BSE Circular/Listings	Mr. Shailendra Pathak is not debarred from holding office of Director by virtue of any SEBI order or any other authority.




The meeting commenced at 11:00 A.M. and concluded at 11:30 A.M.

Kindly take the above information on your records.

Thanking You,

For Beryl Drugs Limited


Sudhir Sethi
Chairman & Director
DIN: 00090172





BERYL DRUGS LIMITED

Regd. Off.: Ground Floor, 133, Kanchan Bagh, Indore - 452001 (M.P.)

Tel. : (0731) 2517677 | E-mail : beryldrugs25@yahoo.com | CIN : L02423MP1993PLC007840

THE CERTIFIED TRUE COPY OF THE RESOLUTIONS PASSED AT THE EXTRA-ORDINARY GENERAL MEETING OF THE BERYL DRUGS LIMITED HELD ON MONDAY, THE 11th DAY OF MAY, 2026 AT 11.00 A.M. AT KANCHAN PALACE, COMMUNITY HALL, NIPANIA RING ROAD INDORE (M.P.)

REGULARIZED THE APPOINTMENT OF MR. SHAILENDRA PATHAK (DIN: 11169772), AS A WHOLE TIME DIRECTOR OF THE COMPANY

“RESOLVED THAT pursuant to the provisions of Sections 152, 196, 197 and other applicable provisions, if any, of the Companies Act, 2013, and the rules made thereunder (including any statutory modification(s) or re-enactment thereof for the time being in force), and in accordance with the Articles of Association of the Company, the appointment of Mr. Shailendra Pathak (DIN: 11169772), who was appointed as an Additional Director and designated as Whole Time Director of the Company by the Board of Directors in the Board Meeting dated 3rd January 2026, who holds office up to the date of this General Meeting in terms of Section 161(1) of the Companies Act, 2013, be and is hereby regularized and approved as a Whole Time Director of the Company for a period of 5 (Five) years with effect from 11th May, 2026, liable to retire by rotation.

RESOLVED FURTHER THAT the approval of the members of the Company is hereby accorded to approve the terms and conditions of his appointment including remuneration, including the remuneration to be paid in the event of loss of inadequacy of profits of the Company and to revise the same from time to time within the limits prescribed under the Companies Act, 2013 and Schedule V thereto as set out in the Explanatory Statement annexed to the Notice convening this Meeting.

RESOLVED FURTHER THAT any Director of the Company be and is hereby severally authorized to file the necessary forms with the Registrar of Companies and to do all such acts, deeds, matters and things as may be necessary, desirable or expedient to give effect to this resolution.”

// CERTIFIED TRUE COPY //

For Beryl Drugs Limited


Sudhir Sethi
Chairman & Director
DIN NO: 00090172



EXPLANATORY STATEMENT

ITEM NO. 1: TO REGULARIZE THE APPOINTMENT OF MR. SHAIENDRA PATHAK (DIN: 11169772) AS WHOLE TIME DIRECTOR OF THE COMPANY:

Mr. Shailendra Pathak was appointed as an Additional Director designated as Whole-Time Director of the Company by the Board of Directors of the Company in their meeting held on 3rd January 2026 pursuant to Section 161(1) of the Companies Act, 2013. His appointment was valid up to the conclusion of the next general meeting of the Company subject to the approval of the members of the Company.

Accordingly in terms of the requirements of the provisions of the Companies Act, 2013, approval of the members of the Company is required for regularisation of the appointment of Mr. Shailendra Pathak as the Whole Time Director of the Company. Hence the Board recommends Resolution No. 1 set out in the Notice for approval of the members by way of Ordinary Resolution.

Mr. Shailendra Pathak is an Engineer by qualification and having more than 35 experience in pharmaceutical industry, specialising in IV fluids and Oral Solid Doses (OSD) manufacturing and has experience in setting up state of the art pharmaceutical plants to commercial production and its marketing.

In addition to the above, the said appointment is desirable and would be beneficial to the Company and the Board recommends to the shareholders to approve the appointment of Mr. Shailendra Pathak as the Whole Time Director for the period of 5 years effective from this EGM, on the terms and conditions as below:

Terms and conditions:

1. Tenure of appointment of Mr. Shailendra Pathak as Whole Time Director shall be for a period of Five Years w.e.f. from the conclusion of this EGM.
2. Remuneration: Mr. Shailendra Pathak will be paid a fixed remuneration of Rs. 1,25,000/- per month and commission of 0.25% of the sale of the Company's products Upto the extent of existing sale and commission of 0.50% of the additional sale of the Company's products.

